RxDoctor Payments DataLook up a doctor →

Jennifer Anderson, MD

Medical Oncology · Gainesville, GANPI 1457748451

Payments from drug & device makers

$11,935in general payments, 2019–2025

Across 359 payments — averaging $33.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Novartis$2K
  • Pfizer$710
  • Bristol Myers Squibb$582
  • Merck$572
  • Gilead$396
  • plus $5K from 54 others

What the payments were for

  • Travel & lodging$2,81924%
  • Food & beverage$7,55863%
  • Education$3933%
  • Other$1,16510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,935 in reported general payments places this provider in the 40th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$1,414,171
Medicare patients
205
Services billed
46,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax31$363,535
IbrancePalbociclib13$211,923
BrukinsaZanubrutinib12$180,611
Abiraterone Acetate37$129,762
EliquisApixaban78$55,936
XareltoRivaroxaban17$9,487
Ondansetron OdtOndansetron71$2,052
Letrozole103$1,957
Anastrozole126$1,474
Oxycodone Hcl65$1,197
Mirtazapine51$1,163
Gabapentin58$869
Acyclovir69$859
Ondansetron Hcl11$765
Dexamethasone26$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$365$363,53531 claims
PfizerIbrance, Eliquis$710$267,85991 claims
Beigene USA, Inc.Brukinsa$82$180,61112 claims
Johnson & JohnsonXarelto$369$9,48717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 68 medical oncology providers in Georgia.

Other medical oncology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →